
The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

